NCT04908787 2025-09-11
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Completed
Clinical Trials
40 trialsNCT03517449 2025-06-15
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT02312245 2024-12-05
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Mayo Clinic
Phase 2 Completed
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT02580058 2023-07-10
JAVELIN Ovarian 200
Pfizer
Phase 3 Completed
NCT02978495 2022-12-28
Neoadjuvant Carboplatin in Triple Negative Breast Cancer
Barretos Cancer Hospital
Phase 2 Completed
NCT03287375 2022-10-07
PIPAC-OPC2
Odense University Hospital
Phase 2 Completed
NCT03604653 2022-08-03
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center, Inc.
Completed
NCT01809379 2022-07-08
Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer
Ruhr University of Bochum
Phase 2 Completed
NCT02475772 2022-07-08
A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis
Ruhr University of Bochum
Phase 1 Completed
NCT00063999 2021-10-19
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
GOG Foundation
Phase 3 Completed
NCT00262990 2020-12-17
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
Phase 3 Completed
NCT02604784 2020-09-17
PI-CaP
Fondazione del Piemonte per l'Oncologia
Phase 1/2 Completed
NCT01459380 2019-07-22
Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00003214 2019-05-15
Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer
Swiss Cancer Institute
Phase 3 Completed
NCT01489371 2019-03-12
EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00662233 2018-10-09
Combination Chemotherapy in Treating Patients With Sarcoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00484432 2018-09-27
Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Advanced or Metastatic Ovarian Cancer
AGC Biologics S.p.A.
Phase 2 Completed
NCT01358071 2018-09-27
NGR018
AGC Biologics S.p.A.
Phase 2 Completed
NCT01767155 2018-07-31
ZoptEC
AEterna Zentaris
Phase 3 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00722293 2017-11-13
A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02320448 2017-09-12
Treating Peritoneal Carcinomatosis With PIPAC
Odense University Hospital
Phase 2 Completed
NCT00575952 2017-08-24
Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
GOG Foundation
Phase 1 Completed
NCT03034850 2017-01-27
Thrombin Generation and Platelet Activation in CRS/HIPEC
Ziekenhuis Oost-Limburg
Completed
NCT01637532 2016-01-26
PITCH
Leiden University Medical Center
Phase 1/2 Completed
NCT01815294 2015-12-04
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
Janssen Research & Development, LLC
Phase 1 Completed
NCT00945139 2015-07-31
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
New Mexico Cancer Research Alliance
Phase 2 Completed
NCT00006011 2015-05-19
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
GOG Foundation
Phase 3 Completed
NCT00005830 2014-12-31
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
GOG Foundation
Phase 1 Completed
NCT00282087 2014-12-01
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00002641 2014-08-08
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002493 2014-02-14
Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer
GOG Foundation
Phase 3 Completed
NCT00025441 2013-12-04
Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00002489 2013-06-26
Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00006377 2013-06-18
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00052312 2012-09-24
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00002764 2012-07-11
Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002526 2012-05-15
Chemotherapy in Treating Patients With Advanced Sarcoma
Swiss Cancer Institute
Phase 2 Completed
NCT00216645 2011-05-17
Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therapy in Patients With Mullerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having Prior Platinum-Based Chemotherapy
Janssen Pharmaceutical K.K.
Phase 2 Completed